Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases
Clinical trial NCT06483672 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06483672
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-01
- Primary completion
- 2025-12-31
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.